Isolation of a novel gene underlying batten disease, CLN3  by Lerner, Terry J et al.
Cell, Vol. 82, 949-957, September 22, 1995, Copyright © 1995 by Cell Press 
Isolation of a Novel Gene 
Underlying Batten Disease, CLN3 
The International Batten Disease Consortium* 
Summary 
Batten disease (also known as juvenile neuronal ceroid 
lipofuscinosis) is a recessively inherited neurodegen- 
erative disorder of childhood characterized by pro- 
gressive loss of vision, seizures, and psychomotor dis- 
turbances. The Batten disease gene, CLN3, maps to 
chromosome 16p12.1. The so-called 56 chromosome 
haplotype defined by alleles at the D'16S299 and 
D16S298 loci is shared by 73% of Batten disease chro- 
mosomes. Exon amplification of a cosmid containing 
D16S298 has yielded a candidate gene that is disrupted 
by a 1 kb genomic deletion in all patients carrying the 
56 chromosome. Two separate deletions and a point 
mutation altering a splice site in three unrelated fami- 
lies have confirmed the candidate as the CLN3 gene. 
The disease gene encodes a novel 438 amino acid pro- 
tein of unknown function. 
Introduction 
The neuronal ceroid lipofuscinoses (NCLs) are a group of 
inherited neurodegenerative disorders characterized by 
the accumulation of autofluorescent lipopigments (ceroid 
and lipofuscin) in neurons and other cell types (Dyken, 
1988). At least five subtypes are recognized, based on age 
of onset, clinicopathological features, and chromosomal 
location. Inheritance is autosomal recessive for the child- 
hood onset forms, which include infantile (CLN1; Haltia- 
Santavuori disease, MIM256730), classical late infantile 
(CLN2; Jansky-Bielschowsky disease, MIM204500), juve- 
nile (CLN3; Batten or Spielmeyer-Vogt-SjSgren disease, 
MIM304200), and Finnish-variant late infantile (CLN5; 
MIM256731). The primary biochemical defects in these 
disorders are not known. 
Batten disease, the juvenile onset form of NCL, is the 
most common neurodegenerative disorder of childhood. 
Its incidence is estimated at up to 1 in 25,000 births (Ze- 
man, 1974), with an increased prevalence in the northern 
European populations. Clinical onset begins with visual 
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failure between the age of 5 and 10 years. Seizures and 
mental deterioration ensue with relentless decline to 
death, usually in the second or third decade. Diagnostic 
criteria include the presence in many cell types of inclu- 
sions that appear as so-called fingerprint profiles on elec- 
tron microscopy (Wisniewski et al., 1988). The major pro- 
tein component of these abnormal deposits is subunit 9 
of mitochondrial ATPase (Palmer et al., 1992), although 
the genetic defect does not lie in a gene encoding this 75 
amino acid protein (Dyer and Walker, 1993; Yan et al., 
1994). 
The loci for several NCL subtypes have been mapped 
by linkage analysis to different chromosomal regions. The 
gene for Batten disease, CLN3, was assigned to human 
chromosome 16 by demonstration of linkage to the hapto- 
globin locus (Eiberg et al., 1989). A collaborative effort 
has allowed progressive refinement of the genetic localiza- 
tion of CLN3 (Gardiner et al., 1990; Callen et al., 1991; 
Yan et al., 1993; Mitchison et al., 1993; Lerner et al., 1994) 
with the aim of isolating the defective gene. Analysis of 
recombinations using a high resolution map of microsatel- 
lite marker loci has defined D16S288 and D16S383 as 
flanking markers and has thereby confined CLN3 to an 
interval of 2.1 cM in 16p12.1-11.2 (Mitchison et al., 1994). 
Within this candidate region, four microsatellite loci, 
D16S288, D16S299, D16S298, and SPN, display strong 
linkage disequilibrium with CLN3 (Mitchison et al., 1993, 
1994, 1995; Lerner et al., 1994), and analysis of haplo- 
types on disease chromosomes suggests that CLN3 lies 
closest to D16S299 and D16S298 (see Figure 1). A core 
56 chromosome haplotype, based on the 5 allele at 
D16S299 and the 6 allele at D16S298, is present on 73% 
of disease chromosomes and on only 3% of control non- 
disease chromosomes. The 6 chromosome allele at 
D16S298 is present on 96% of Finnish Batten disease 
chromosomes, suggesting that CLN3 is close to this 
marker (Mitchison et al., 1995). This is supported by the 
finding that two unusual patients have apparent deletions 
of D 16S298: a Moroccan patient (NCL39.3) from a consan- 
guinous relationship homozygous for the absence of 
D16S298 as part of a cytogenetically undetectable micro- 
deletion (Taschner et al., 1995a) and a Finnish patient 
(L199Pa) hemizygous for D16S298 (Mitchison et al., 1995; 
this paper). 
We now report the identification of the Batten disease 
gene, defined by cDNA (clone 2-3), from a cosmid con- 
taining D16S298. The gene is disrupted by a small (1.02 
kb) deletion on all Batten disease chromosomes with the 
56 chromosome haplotype and by the independent dele- 
tions in the Finnish and Moroccan patients mentioned 
above. In another unrelated Batten disease family, we 
have identified a point mutation that segregates with the 
disease and alters an invariant base of a 5' donor splice 
site. The Batten disease gene, CLN3, possesses an open 
reading frame of 1314 bp encoding a predicted 438 amino 
acid protein product with no significant similarity to pre- 
viously described proteins. The discovery of this disease 
gene will permit direct genetic diagnosis of Batten disease 
and represents an initial step to understanding the patho- 
genesis of this disorder. 
Results 
Isolation and Characterization of cDNA2-3 
Previously, we described a cosmid walk from D16S48 in 
Los Alamos contig c343.1 (Stallings et al., 1992) toward 
D16S299, yielding the 185 kb contig cNL/343.1 (Taschner 
et al., 1995a) (Figure 1). Cosmid NL11A, the most distal 
cosmid in this contig, was found to contain the D16S298 
locus and to encompass the region deleted in the Moroc- 
can patient NCL39.3. These findings implicate NL11A as 
the most likely site of CLN3. Thus, in this study, we targeted 
this cosmid for saturation with candidate Batten disease 
gene transcripts. 
A 180 bp exon isolated from NLl lA by exon amplifica- 
tion (Buckler et al., 1991; Church et al., 1994; Lerner et 
al., 1995) was used to screen a fetal brain cDNA library 
(Stratagene), yielding a 1.7 kb cDNA (clone 2-3). The re- 
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Figure 1. Schematic Representation of the 
CLN3 Candidate Region on Chromosome 
16p12.1 
Adapted from Jfirvelfi et al. (1995a, 1995b). 
The positions of selected DNA microsatellites 
used for linkage and haplotype analysis are in- 
dicated. Individual cosmids (NL11A and 
NL6OD3) of cosmid contig CNL/343A, which 
contains D16S298 and D16S48, and cosmid 
contig C182, which contains D 16S299, are indi- 
cated. Three yeast artificial, chromosomes 
(Cy21 B11, Cy302G12, and Cy85D3) that form 
part of a 980 kb contig spanning the candidate 
region are indicated by horizontal lines. Pstl 
restriction fragments of NL11A that could be 
ordered are shown. The genomic extent of 
cDNA2-3 is shown below the map, with the 
arrow indicating the direction of transcription. 
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Figure 2. Northern Blot Analysis of cDNA2-3 
cDNA2-3 was hybridized to a Northern blot (CIontech) containing 2
I~g of poly(A) ÷ RNA per lane from heart (lane 1), brain (lane 2), placenta 
(lane 3), lung (lane 4), liver (lane 5), skeletal muscle (lane 6), kidney 
(lane 7), and pancreas (lane 8). The filter was washed at 50°C in 0.1 x 
SSC and exposed for 24 hr. An - 1.7 kb transcript can be seen in all 
the tissues tested. 
suits of Southern blot and polymerase chain reaction 
(PCR) analyses of genomic and cosmid DNAs showed that 
the 1.7 kb cDNA is contained in NL11A and that transcrip- 
tion proceeds toward D16S299 (Figure 1). PCR amplifica- 
tion of individual Pstl fragments of NL11A using the 
D16S298 microsatellite primers placed D16S298 on a 1.3 
kb Pstl fragment previously shown to be contained within 
the deletion of the Moroccan patient (Taschner et al., 
1995a). This fragment is not detected by cDNA2-3, but 
consists of intron sequences mapping between bases 
1193 and 1194 (see Figure 3) of the cDNA (H. M. M., 
unpublished data). Thus, cDNA2-3 spans the D16S298 
locus and overlaps with the deletion found in the Moroccan 
patient. 
Northern blot analysis using cDNA2-3 as probe revealed 
a 1.7 kb transcript in poly(A) mRNA isolated from a wide 
variety of human tissues, including heart, brain, placenta, 
lung, liver, skeletal muscle, kidney, and pancreas (Figure 
2), consistent with the cDNA clone being nearly full length. 
The transcript is not detected by Northern blot analysis in 
cultured lymphoblasts and in fibroblasts, but is detectable 
by reverse transcription PCR (RT-PCR) analysis of poly(A) 
mRNA isolated from such cell lines. A so-called zoo blot 
containing genomic DNAs from several animal species 
showed that this gene is conserved in mammals. Strong 
signals were obtained from mouse, sheep, cow, and pig 
(data not shown). 
Sequence Analysis of cDNA2-3 
Figure 3 shows the sequence of the cDNA that spans 1689 
bp and has a 47 base poly(A) tail. A predicted open reading 
frame of 1314 bp begins with a potential initiator ATG co- 
don at base 138 and ends with a TGA termination codon 
at base 1452. An in-frame stop codon is located 36 bases 
upstream of the initiator site, and a consensus polyadenyl- 
ation site is located at base 1666. The predicted product 
of the cDNA is a protein of 438 amino acids with a molecu- 
lar mass of 48 kDa. 
The cDNA sequence was compared against the Gen- 
Bank and dbEST databases using BLASTN (Altschul et al., 
1990) and FASTA (Pearson and Lipman, 1988) sequence 
alignment algorithms. These searches revealed no signifi- 
cant similarities to genes of known function. However, 
near identity (>95% similarity) was found to 13 expressed 
sequence tags (ESTs) (F11432, F12401, T74504, T08995, 
R12998, Z42735, T47968, D20292, T47969, T97772, 
F09095, F10019, and T61330) isolated from five indepen- 
dent cDNA libraries (infant brain, fetal spleen, fetal liver 
and spleen, adult liver, and promyelocyte cell line HL60). 
Three pairs of ESTs (F11432/F09095, F12401/F10019, 
and T47968/T47969) are 5' and 3' sequences of three 
cDNA clones. Five ESTs (Fl1432, F12401, T74504, 
T08995, and R 12998), all isolated from a normalized infant 
brain cDNA library (Soares et al., 1994), are missing bases 
184-262 of cDNA2-3 (Figure 3). If the same initiator ATG 
is used, this transcript is expected to produce a truncated 
protein of only 27 amino acids and, thus, is unlikely to 
be the result of normal RNA splicing. The physiological 
significance of this variant is unclear, since its relative 
abundance may be exaggerated by preparation of the nor- 
malized cDNA library. 
The predicted protein sequence was compared against 
the SwissProt database using BLASTP and Smith-Water- 
man (Smith and Waterman, 1981) sequence alignment 
algorithms and against the predicted translation products 
of GenBank database using TBLASTN. In all these cases, 
no significant similarities were found to known proteins. 
A search of the BLOCKS database (version 8.0; Henikoff 
and Henikoff, 1994) for motifs found only single blocks of 
homology for any group of proteins, and this could be 
attributed to chance. A search for protein motifs in the 
CLN3 protein using the ProSite Database (version 12.2) 
revealed pattern matches for four N-glycosylation sites, 
two glycosaminoglycan attachment sites, two cAMP- and 
cGMP-dependent protein kinase phosphorylation sites, 
six protein kinase C phosphorylation sites, eight casein 
kinase II phosphorylation sites, and 12 N-myristoylation 
sites (Figure 3). Hydropathy calculations (Kyte and Doolit- 
tie, 1982) predicted five hydrophobic regions that may be 
potential membrane-spanning regions at amino acids 38- 
61, 93-233, 278-310, 345-399, and 408-438. 
The Common Mutation Is A Small Deletion 
To screen for possible deletions, insertions, and other 
chromosomal rearrangements a sociated with the clone 
2-3 gene, we scanned conventional Southern blots of re- 
striction-digested DNA from unrelated Batten disease pa- 
tients. Figure 4a shows the results of hybridizing a panel 
of Pstl-digested patient DNAs with PCR probes P1-P3 and 
P2-P5, representing the 5' and 3' halves of the cDNA, 
respectively. When the P1-P3 fragment was used as 
probe, affected individuals homozygous for the D16S299/ 
D16S298 56 chromosome haplotype (Figure 4a, lanes 
1-3) displayed the loss of a 3.8 kb Pstl fragment and the 
gain of a novel 2.8 kbp fragment. When the P2-P5 frag- 
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Figure 3. The Nucleotide Sequence of cDNA2-3 
The predicted protein is shown below the DNA sequence, assuming 
that ranslation begins at the first in-frame methionine ofthe long open 
reading frame. Four potential N-linked glycosylation sites are indicated 
by a broken line at residues 49, 71, 85, and 310 (Bause, 1983). Two 
potential glycosaminoglycan sites are indicated by the dotted lines at 
residues 162 and 186 (Bourdon et al., 1987). Potential N-myristoylation 
sites are indicated by a number sign (Grand, 1989). Serine and threo- 
nine residues that are potentially phosphorylated bycAMP- and cGMP- 
dependent protein kinases (indicated by a percent sign) (Glass et al., 
1986), by protein kinase C (indicated by an asterisk) (Woodgett et al., 
1986), or by casein kinase II (indicated by a caret) (Pinna, 1990) are 
shown. The polyadenylation site at base 1666 is indicated by a dollar 
ment was used as probe, no difference was detected be- 
tween controls and the homozygous 56 chromosome 
haplotype affected patients. Analysis of 148 control chro- 
mosomes, including seven with the 56 chromosome hap- 
Iotype, revealed no alterations. The affected individuals 
bearing a 56 chromosome also displayed altered frag- 
ments with Hindlll and Pvull digestion (data not shown), 
suggestive of a small ( -  1000 bp) genomic deletion of the 
56 chromosome. Figure 4b illustrates the Mendelian inher- 
itance of this deletion in a two-generation Batten disease 
family segregating the 56 chromosome haplotype. 
To determine the effect of this genomic deletion on the 
clone 2-3 transcript, we performed PCR amplification of 
RT cDNA from patients homozygous for the 56 chromo- 
some haplotype. The P1-P3 primer pair yielded a novel 
product that was -200  bp smaller than that predicted 
from the cDNA sequence and that was found in all non- 
56 chromosome normal controls (Figure 4c). RT-PCR am- 
plification with the P2-P5 primer pair yielded identical 
- 800 bp products in affected patients and controls. DNA 
sequence analysis of the P1-P3 product from five homozy- 
gous 56 chromosome patients showed in all cases a 217 
bp deletion, from base 598 to base 814 of the cDNA (see 
Figure 3). The DNA sequence of the RT cDNA from four 
control individuals revealed no evidence of deletion, 
matching the cDNA2-3 sequence. Deletion of these 217 
bases of coding sequence produces a frameshift, generat- 
ing a TAA termination codon 84 bp downstream of the 
deletion junction. The predicted translation product is a 
truncated protein of 181 amino acids consisting of the first 
153 residues of the protein followed by 28 novel amino 
acids before the stop codon. 
DNA sequence analysis of the genomic fragment con- 
taining this deletion from a 56 chromosome homozygous 
patient revealed the loss of 1.02 kb of genomic sequence 
(Figure 5a). The intron sequence immediately 5' to the 
deletion is 91% homologous to bases 84-290 of the Alu- 
Sx family consensus sequence in the 5' to 3' orientation. 
The A-rich sequence at the 3' end of this Alu sequence 
includes a (GA)n repeat within the 5' deleted segment. The 
sequence at the 3' portion of the deleted region is 87% 
homologous to bases 1-290 of the Alu-Sx sequence, also 
in the 5'to 3' orientation, and contains a (GA)o repeat within 
the A-rich sequence of the 3' tail. Included in this deletion 
are 217 bp of the open reading frame (base pairs 598- 
814; see Figure 3), corresponding to two exons. 
Screening for the 56 Chromosome Deletion 
PCR amplification of genomic DNA with primers F2 and 
P3 flanking the cDNA deletion produces a 3.5 kb product 
from normal chromosomes and a 2.5 kb product from the 
chromosomes with the 1.02 kb deletion described above. 
sign. cDNA sequences deleted in the 56 chromosome deletion (bases 
598-814) and the L199Pa deletion (bases 928-1193) are shown in 
boxes. The positions of forward PCR primers used in these studies 
are as follows: P1, bases 39-58; F2, bases 552-569; F4, bases 676- 
695; F5, bases 778-797; P2, bases 860-879;/=9, bases 888-907; GF1, 
bases 1470-1487. The positions of the reverse primers are as follows: 
R1, bases 658-637; P3, bases 880-861; R5, bases 1246-1229; R3, 
bases 1612-1595; GR1, bases 1661-1643; P5, bases 1669-1651. 
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Figure 4, Analysis of cDNA2-3 in Batten Disease Patients 
(a) Southern blot analysis of cDNA2-3 in Batten disease patients. Ge- 
nomic DNA was digested with Pstl, subjected to agarose gel electro- 
phoresis, and transferred to Hybond N ÷ membrane (Amersham). 
Lanes 1-3, patients homozygous for the 56 chromosome alleles; lane 
4, unaffected control; lane 5,patient heterozygous for the 56 chromo- 
some alleles (see text for data on patient L199Pa). The left panel was 
probed with a radiolabeled PCR fragment amplified from cDNA2-3 
using primers P1-P3, corresponding tothe 5' half of the cDNA. The 
right panel was probed with a radiolabeled PCR fragment amplified 
from cDNA2-3 using primers P2-P5, corresponding to the 3' half of 
the cDNA. 
(b) Southern blot analysis of cDNA2-3 in a family with an affected child 
homozygous for the 56 chromosome haplotype. Southern blots were 
prepared as described above and hybridized with the P1-P3 probe• 
The affected individual is shown by the closed symbol and carriers 
by the half-closed symbols. Progeny are shown by diamonds, and the 
birth order of some individuals h s been changed for confidentiality. 
The chromosomes segregating i  this pedigree have been distin- 
guished by extensive typing with polymorphic markers in 16p12.1-11.2 
(Lerner et al., 1994). 
We tested for the presence of the 1.02 kb deletion associ- 
ated with the D16S299/D16S298 56 chromosome haplo- 
type in 81 unrelated Batten patients representing 24 haplo- 
types and originating from 16 countries (Table 1). Of these, 
46 were homozygous for the 56 chromosome haplotype, 
24 were heterozygous for the 56 chromosome haplotype, 
and 11 did not carry the 56 chromosome haplotype on 
either chromosome. In all 70 patients with an affected 56 
chromosome, the 2.5 kb fragment was detected, and in all 
46 homozygotes for this haplotype, no normal size product 
was produced. Smaller numbers of chromosomes bearing 
closely related haplotypes (66, 36, 46, 57, and 55) also 
carried this deletion, suggesting that these chromosomes 
most probably derived from the 56 chromosome haplotype 
by mutation of the polymorphic marker o recombination. 
Additional affected chromosomes bearing the 66 and 46 
chromosome haplotypes apparently possess mutations 
independent of the 56 chromosome, as they do not carry 
this deletion. Thus, the 1.02 kb genomic deletion of the 
clone 2-3 gene associated with the 56 chromosome haplo- 
type is the most common mutation in Batten disease, ac- 
counting for 81% of disease chromosomes tested to date. 
Other Mutations Disrupting the Gene 
Haplotype analysis of Finnish patient L199Pa revealed 
one 56 chromosome and one @null chromosome, exhib- 
iting absence of any D16S298 allele (for clinical details 
see Experimental Procedures). Southern blot analysis of 
this patient (see Figure 4a, lane 5) revealed two alterations: 
the 1.02 kb deletion typical of the 56 chromosome haplo- 
type and a second deletion present on the chromosome 
missing D16S298 that results in the formation of a novel 
1.5 kbjunction fragment. This junction fragment combines 
sequences from an upstream 1.1 kb Pstl fragment de- 
tected by the cDNA probe and from a Pstl fragment 3' to 
D16S298 that contains only intron sequence. PCR analy- 
sis of patient DNA using the i ntron primer IntR 14 and cDNA 
primer F9 confirmed an - 3 kb deletion, including the en- 
tire 1.3 kb Pstl fragment containing D16S298 (Figure 5b). 
RT cDNA from this second mutant allele was selectively 
amplified using primer R5 and primer FS, which is deleted 
on the 56 chromosome. The amplified product revealed 
the absence of 266 bp of coding sequence between bases 
928 and 1193 of the cDNA (see Figure 3), generating a 
TGA termination codon 84 bp downstream of the deletion 
junction. The predicted translation product is a truncated 
protein of 291 amino acids consisting of the first 263 amino 
acids of the protein followed by 26 novel amino acids be- 
fore the stop codon. Partial DNA sequence analysis of 
the genomic fragment containing this -3  kb deletion has 
confirmed the loss of bases 928-1193 of the cDNA. 
(c) RNA analysis of cDNA2-3 in Batten disease patients. RT cDNA 
was prepared from cytoplasmic RNA and amplified using either primer 
pair P1-P3 (top) or P2-P5 (bottom). The PCR products were fraction- 
ated on 1.5o/o agarose gels, transferred to Hybond N ÷ (Amersham) 
membranes, and hybridized with the corresponding probe• Lanes 
1-6, RNA from peripheral blood lymphocytes of control individuals; 
lane 7, water PCR control; lanes 8 and 10-12, RNA from fibroblasts 
of patient homozygous for the 56 chromosome haplotype; lane 9, RNA 
from fibroblasts of control individual• 
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Figure 5. Genomic Deletions of CLN3 
(a) Genomic deletion of 1.02 kb in disease chro- 
mosomes bearing the 56 chromosome haplo- 
type. The complete sequence of the deletion 
is known, but only the sequences bordering the 
deletion are shown. The deletion covers two 
exons and the flanking intronic sequence and 
leads to the deletion of 217 bp of coding se- 
quence. Positions of primers F2, R1, and P3, 
used to delineate the deletion, are indicated. 
Hatched boxes represent exons. The deletion 
breakpoints are shown by the arrows, and de- 
leted sequences are shown in italics. The posi- 
tions of flanking Alu-Sx sequences are indi- 
cated. 
(b) Schematic representation of the genomic 
deletions of the CLN3 gene. Position of primers 
used to delineate the deletions are indicated. 
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We previously described a homozygous deletion of the 
D16S298 locus in a Batten patient of Moroccan origin 
(NCL39.3). Although the size of the deletion was not deter- 
mined, it did include the 1.3 kb Pstl fragment containing 
D16S298 (Taschner et al., 1995a), which has proved to 
Table 1. Deletion Analysis of Batten Disease Patients 
PCR 
Amplification 
Product 
Haplotype 
D16S199/D16S298 2.5 kb 3.5 kb 
Number of 
Chromosomes" 
56 + - 116 
- + 0 
66 + - 4 
- + 7 
36 + - 4 
- + 0 
46 + 2 
- + 1 
65 + - 1 
- + 0 
67 + - 1 
- + 0 
57 + - 2 
- + 0 
55 + - 1 
- + 0 
Other haplotypes + - 1 
- + 22 
Genomic PCR was carried out using primer pair F2-P3 at bases 552 
and 880 of the cDNA2-3 sequence. PCR amplification was carried out 
as described in Experimental Procedures. 
a Total number of chromosomes was 162. 
be within an intron of the clone 2-3 candidate gene. PCR 
amplification of genomic DNA with primers F2 and R3 
yielded a 1.1 kb fragment instead of the expected -7  kb 
fragment (Figu re 5b). Additional PCR amplifications using 
nested primers on either the 5' (F4-R3) or 3' (GF1-GR1) 
sides gave no product, suggesting a deletion in the Moroc- 
can patient of -6  kb that starts between F2 and F4 and 
ends between GF1 and R3. 
Single-stranded conformation polymorphism (Orita et 
al., 1989) was performed to scan the CLN3 gene for further 
mutations. Patient L198Pa (for clinical details see Experi- 
mental Procedures), who is heterozygous with one 56 chro- 
mosome and one 76 chromosome (D16S299/D16S298), 
exhibited a mobility shift in a 73 bp exon corresponding 
to bases 598-670 of the cDNA (data not shown). Nucle- 
otide sequence analysis showed a G to C transition at +1 
of the splice donor site following the exon. Analysis of the 
parents of patient L198Pa showed the father (haplotype 
76•46) to be a heterozygous carrier of this mutation. 
Discuss ion  
The results of haplotype analysis of 142 families sug- 
gested that the major Batten disease mutation occurred on 
an ancestral chromosome bearing the D 16S299/D 16S298 
56 chromosome haplotype (Mitchison ~pt al., 1994). The 
data presented here provide compelling evidence that this 
mutation is a 1.02 kb deletion that implicates cDNA2-3 as 
the product of CLN3. This deletion involves the 3' end of 
two Alu-Sx elements and the following (GA)o sequence 
and may therefore have arisen by recombination involving 
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bordering Alu sequences, a mechanism for which other 
examples exist in human disease (e.g., Rudiger et al., 
1995). The deletion mutation is found on all affected 56 
chromosomes examined to date and on several chromo- 
somes with related haplotypes, accounting for 81% of Bat- 
ten disease chromosomes. 
Studies are in progress to characterize the mutations 
of the clone 2-3 gene found on the minority of disease 
chromosomes that do not carry the 1.02 kb deletion. With 
the notable exceptions of patients L199Pa and NCL39.3, 
Southern blot and long-range PCR analyses of patients 
with chromosomes lacking the 1.02 kb deletion have failed 
to reveal additional genomic rearrangements. These re- 
sults suggest that these affected chromosomes most 
likely carry point mutations, small deletions, or regulatory 
mutations of CLN3, e.g., the altered splice site in pa- 
tient L198Pa. The independent deletions in L199Pa and 
NCL39.3, both of which encompass the D16S298 micro- 
satellite locus, provide the strongest confirmatory evi- 
dence that cDNA2-3 is the product of CLN3. Ultimate 
proof, however, that cDNA2-3 represents CLN3 will require 
the reversal of the disease phenotype in a cell or animal 
model system or the generation of knockout animals that 
exhibit a Batten disease-like phenotype. 
No homology has been found at the nucleotide or amino 
acid level with any previously identified gene, indicating 
that CLN3 encodes a novel protein of (as yet) unknown 
function. Diverse approaches may now be used to explore 
the normal physiological role of the CLN3 protein. For ex- 
ample, the conservation of coding sequences across spe- 
cies should allow the identification of homologous se- 
quences and target conserved domains of functional 
significance. The presence of several potential phosphory- 
lation sites suggests that the protein may undergo phos- 
phorylation as a prerequisite for binding an additional pro- 
tein(s). The PSORT program (version 6.3; Nakai and 
Kanehisa, 1992) for prediction of protein localization sites 
indicates that the CLN3 protein may be a type IIIb mem- 
brane protein (Heijne and Gavel, 1988), a possibility sup- 
ported by hydropathy calculations that suggest the pres- 
ence of several hydrophobic domains and by numerous 
potential N-glycosylation and N-myristoylation sites. 
The deletions identified to date are predicted to remove 
>100 amino acids from the C-terminal portion of the CLN3 
protein, suggesting that its normal function would be se- 
verely compromised in the disease. However, it is also 
conceivable that the disease phenotype may involve ab- 
normal accumulation of truncated protein products rather 
than or in addition to direct loss of protein function. The 
CLN3 gene is expressed not only in the brain, the site of 
massive neuronal cell death in Batten patients, but also 
in a wide range of tissues. Consistent with this, inclusion 
bodies have been found in many Batten disease tissues 
in addition to the brain. Palmer et al. (1992) demonstrated 
the abnormal accumulation of subunit 9 of mitochondrial 
ATPase in these inclusions, but experiments mapping the 
subunit 9 genes P1 and P2 to chromosomes 17 and 12, 
respectively (Dyer and Walker, 1993), and P3 to chromo- 
some 2 (Yan et al., 1994) excluded these genes as the 
site of the Batten disease defect. It will now be of interest o 
determine whether the CLN3 protein or fragments thereof 
also accumulate in the disorder. Similarly, various bio- 
chemical approaches have suggested that Batten disease 
involves perturbations in several metabolic pathways, in- 
cluding, for example, lipid peroxidation (Siakotos et al., 
1988), metabolism of dolichol-linked oligosaccharides 
(Hall and Patrick, 1985), and lysosomal proteinase activity 
(Wolfe et al., 1987). Whether these diverse biochemical 
phenotypes are the result of the primary gene defect or 
are secondary effects of the disease process can now be 
examined. 
Because of the slow progression of symptoms in Batten 
disease and its similarity to other NCL subtypes and neuro- 
logic disorders, diagnosis is often missed or delayed. Cur- 
rent diagnostic protocols call for examination of skin biop- 
sies for hallmark fingerprint profiles in inclusion bodies, a 
technically demanding procedure. Since the demonstra- 
tion of linkage disequilibrium, carrier detection by haplo- 
type analysis has been possible (Taschner et al., 1995b). 
The direct PCR assay for the 56 chromosome deletion 
described in this paper will imp.rove the reliability of the 
diagnosis for the majority of Batten disease patients and 
provide families with the opportunity for prenatal and car- 
rier testing. 
The identification of the Batten disease gene is the initial 
step in understanding the pathology underlying this com- 
plex disorder. This study provides the basis for analyzing 
the role of the CLN3 protein in both normal and disease 
cells and provides a starting point for the design of rational 
therapies. Moreover, what we learn from studying the 
CLN3 protein may reveal the underlying cause of the other 
ceroid lipofuscinoses and provide insights into the mecha- 
nisms involved in other neurodegenerative disorders. 
Experimental Procedures 
Patients and Cell Lines 
Patients with Batten disease were identified through contacts with 
organizations ofvolunteer parents and through clinical referrals. Diag- 
noses were confirmed using standard criteria (Boustany et al., 1988; 
Santavuori, 1988). The establishment of lymphoblastoid cell lines was 
previously described (Anderson and Gusella, 1984). Finnish patient 
L199Pa had a normal birth and early childhood. At age 6.5, he was 
referred to Dr. P. Santavuori at the University of Helsinki Clinic and 
Children's Hospital because of failing vision. Electroretinogram was 
abolished, and visual evoked potential was abnormal with delayed 
latency. Slight motor clumsiness and muscular hypotonia were found. 
Vacuolated lymphocytes were positive on repeated examinations. 
From age 11, he had generalized epileptic seizures that were well 
controlled by sodium valproate-clonazepam. An MRI at age 16 
showed slight central, cortical, and cerebellar atrophy. The patient is 
still able to walk independently, but jumping has become difficult. He 
has finished school and is working in a daycare center. 
Finnish patient L198Pa had an uneventful birth and early childhood. 
Since the age of 7, she has experienced progressive visual failure. 
At age 9, she showed an abnormal MRI. Vacuolated lymphocytes 
were repeatedly observed, and electron microscopy of a rectal biopsy 
specimen showed inclusions typical for Batten disease. She has been 
on sodium valproate medication since the age of 9, when she experi- 
enced her only seizure. Recent examination atthe age of 13 showed 
that her motor status is good but that her mental decline has been 
relatively fast. 
The Moroccan patient has been previously described (Taschner et 
al., 1995a). 
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DNA Electrophoresis and Hybridization 
DNA extraction, restriction digests, electrophoresis, Southern blotting, 
hybridization, and washing were performed by standard methods 
(Sambrook et al., 1989). 
cDNA Screening and Characterization 
Exon amplification was carried out using the pSPL3 vector as de- 
scribed by Church et al. (1994). A human fetal brain cDNA library in 
Z7_.APII (Stratagene) was screened by standard methods using exon 
probes, cDNA clones and trapped exons were sequenced manually 
(Sanger et al., 1977) with Sequenase T7 DNA polymerase (United 
States Biochemicals). 
RNA Procedures 
Cytoplasmic RNA was isolated by standard methods (Sambrook et 
al., 1989) or using RNazol (Biogenesis). RNA was reverse transcribed 
using oligo(dT) or random hexamer primers and Superscript reverse 
transcriptase (GIBCO). Portions of the cDNA were amplified using 
primer sets described in the text. Direct sequencing of PCR products 
was carried out as described previously (McClatchey et al., 1992) or 
by purification with Qiagel (Qiagen) followed by sequencing with an 
Applied Biosystems (ABI) 373A automated sequencer. PCR products 
were subcloned using the TA cloning kit (Invitrogen). 
PCR 
PCR was carried out using Taq polymerase, following the recommen- 
dations of the manufacturer. The assay for the 56 chromosome dele- 
tion was carried out on 100 ng of genomic DNA using primers F2 and 
P3 in a reaction including 0.2 p.M of each primer, 0.2 mM of each 
dNTP, 1.5 mM MgCI2, and 0.5-1 I~1 of AmpliTaq (Perkins-Elmer). In 
one laboratory, the reaction was supplemented with 5 U of TaqEx- 
tender (Stratagene), which was found to enhance the amplification. 
Annealing temperatures ranging between 55°C and 62°C were used 
successfully. Samples were fractionated on an 0.8% agarose gel. 
Genomic Sequencing 
Genomic DNA from a normal control and the somatic cell hybrid 
CY101, which carries a single copy of chromosome 16 derived from 
a patient homezygous for the 56 chromosome hapletype, was PCR 
amplified with primers P1-P3. The resulting PCR products were di- 
gested with Taql. A 1.5 kb fragment was detected in the control, and 
a 0.5 kb fragment was detected in CY101, These two fragments were 
subcloned into pUC19 and sequenced with an ABI 373A automated 
sequencer, In an independent study, the sequence spanning the 56 
chromosome deletion was generated by PCR sequencing of the sub- 
cloned 3.8 kb Pstl fragment using an AB1373A automated sequencer. 
Single-Stranded Conformation Polymorphism Analysis 
Intron primers IntF6 (5'-GGAGCCTCTATGAGCTGATACTG-3') and 
IntR12 (5'-GGAACATTCAGGAGGACCTAGG-3') were used to amplify 
patient DNA for single-stranded conformation polymorphism analysis 
(Orita et al., 1989). Each sample ( -0 .5  p.I) was loaded onto 12,5% 
homogeneous gels, and these were electrophoresed for -200 vh at 
15°C in a PhastSystem apparatus (Pharmacia). Gels were subse- 
quently stained and fixed using the method suggested bythe manufac- 
turer. The patient sample exhibiting a band shift was sequenced using 
the Taq dye deoxy terminator cycle sequencing kit and analyzed using 
the ABI 373A sequencer. 
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